Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: AgFinder who wrote (2507)	4/22/1999 1:09:00 AM
From: Neuroguy	Read Replies (2) \| Respond to of 10280

Art & others... All other issues being equal (like the price of LLY), really, do any of us really understand the price swings of SEPR of late? Those of you who are into options have a tendancy to think of it all in those terms. But is this true? SEPR has been tracking LLY for a long time now. Do the charts... SEPR has become the BCST - it's a tracking stock now. Based on Prozac II, it seems...? Correct me if I'm wrong, but lately this has not been my cause for celebration.... Neuroguy thumbs through E.B. White once more......

To: AgFinder who wrote (2507)	4/23/1999 9:07:00 AM
From: BDR	Read Replies (1) \| Respond to of 10280

<<Dr. David Kessler, the last FDA commissioner, is missed. As a pediatrican, he tried to encourage the development of more pediatric labeling.>> Speaking of pediatric labeling and the FDA: Challenge to FDA pediatric drug rule rejected dailynews.yahoo.com "The suit was filed in February by the National Pharmaceutical Alliance and the Generic Pharmaceutical Industry Association. The two trade groups wanted to block the FDA from implementing new pediatric drug study rules, arguing that the rules were too generous to drug companies that develop new drugs."